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The cholesterol-dependent cytolysins (CDCs) attack cells by punching large holes in their
membranes. Lectinolysin from Streptococcus mitis is unique among CDCs due to the pres-
ence of an N-terminal lectin domain that enhances the pore-forming activity of the toxin.
We recently determined the crystal structures of the lectin domain in complex with various
glycans. These structures revealed the molecular basis for the Lewis antigen speciﬁcity of
the toxin. Based on this information we have used in silico molecular modeling to design
a mutant toxin, which we predicted would increase its speciﬁcity for Lewis y, an antigen
found on the surface of cancer cells. Surprisingly, we found by surface plasmon resonance
binding experiments that the resultant mutant lectin domain exhibited higher speciﬁcity for
Lewis b antigens instead. We then undertook comparative crystallographic and molecular
dynamics simulation studies of the wild-type and mutant lectin domains to understand the
molecular basis for the disparity between the theoretical and experimental results. The
crystallographic results revealed that the net number of interactions between Lewis y and
wild-type versus mutant was unchanged whereas there was a loss of a hydrogen bond
between mutant and Lewis b compared to wild-type. In contrast, the molecular dynamics
studies revealed that the Lewis b antigen spent more time in the binding pocket of the
mutant compared to wild-type and the reverse was true for Lewis y. The results of these
simulation studies are consistent with the conclusions drawn from the surface plasmon
resonance studies. This work is part of a program to engineer lectinolysin so that it will
target and kill speciﬁc cells in human diseases.
Keywords: cholesterol-dependent cytolysins, Lewis antigens, molecular dynamics simulations, protein engineer-
ing, surface plasmon resonance, X-ray crystallography
INTRODUCTION
Lectinolysin (LLY) is a pore-forming toxin derived from some
strains of Streptococcus mitis and S. pseudopneumoniae and is
a member of the cholesterol-dependent cytolysin (CDC) family
(Farrand et al., 2008). These pore-forming bacterial toxins are
secreted as soluble monomers that assemble on the surface of
cholesterol-rich cell membranes. The resultant pores are com-
posed in excess of 30 monomers, and are greater than 150 Å in
diameter (Hotze and Tweten, 2012). Perforation of the membrane
by these pores results in cell lysis. The sequence similarity is high
(40–80%) between CDC family members.
Streptococcus mitis can cause diseases such as infective endo-
carditis and septicemia (Hall and Baddour, 2002; Huang et al.,
2002; Gowda et al., 2003; Kennedy et al., 2004). Serum iso-
lates from Kawasaki disease patients were found to contain S.
mitis human platelet aggregation factor (PAF or Sm-hPAF), so
named because it was found to affect light scattering properties
of human platelets, thought to be as a consequence of platelet
aggregation (Ohkuni et al., 1997). Farrand et al. (2008) found
that the Sm-hPAF gene sequence encodes a predicted CDC struc-
ture (Rossjohn et al., 1997; Polekhina et al., 2005), most closely
related to intermedilysin (Farrand et al., 2008). Having estab-
lished that PAF was in fact a member of the CDC family, it was
renamed lectinolysin, because of its ability to bind carbohydrate
(see below).
While LLY shares a number of characteristics typical of CDCs, it
has a unique 162 amino acid N-terminal domain (LLYlec; Farrand
et al., 2008). Sequence comparisons show that the LLYlec domain
shares signiﬁcant identity with fucose-binding proteins. Glycan
array experiments revealed that LLY was highly selective for the
difucosylated glycans Lewis y (Ley) and Lewis b (Leb) antigens
(Farrand et al., 2008). Small-angle X-ray scattering (SAXS) mod-
eling predicts that LLYlec is joined to CDC domain 1 so that the
Le antigen-binding site is exposed on the outer surface of the pore
(Feil et al., 2012).
Lewis antigens are blood group determinants with very rigid
structures (Yuriev et al., 2005). Leb is a type 1 antigen and adsorbed
onto the surface of blood cells. Ley is a type 2 antigen which, in
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healthy individuals, is expressed at low levels in tissues includ-
ing epithelial cells and serum (Yuriev et al., 2005; Westwood et al.,
2009). However, expression is elevated on the surface of a wide
range of epithelial tumor cells including colon, lung, and ovary
(Sakamoto et al., 1986; Miyake et al., 1992; Yin et al., 1996). Thus,
Ley is a distinctive tumor marker and therefore a promising target
for directing drugs to cancer cells.
Various approaches have been taken to produce Ley-speciﬁc
cancer therapeutics, including the development of Ley-speciﬁc
humanized monoclonal antibodies (Kitamura et al., 1994; Clarke
et al., 2000a,b; Scott et al., 2000), and anti Ley T cells (Westwood
et al., 2005). A chimeric approach has also been taken whereby a
Ley-speciﬁc monoclonal antibody was conjugated to the CDC, lis-
teriolysinO, to forman immunotoxin (Bergelt et al., 2009). LLY is a
naturally occurring, potential oncotoxin, with in-built tumor tar-
geting speciﬁcity for theLey antigen. However, cross reactivitywith
Leb antigen decreases its usefulness as a speciﬁc, cancer-targeting
molecule.
Previously we have determined the crystal structure of LLYlec,
and its complexes with fucose and Leb and Ley antigens (Feil et al.,
2012). The overall fold of the LLYlec domain exhibited similarities
with fucolectin domains of the CBM family 98 glycoside hydrolase
of Streptococcus pneumonia and Anguilla anguilla agglutinin. The
binding of Ley and Leb to LLYlec was very similar with the excep-
tion of an additional hydrogen bond between Leb and amino acid
residue Tyr62 (Feil et al., 2012).
Using these structures, we have explored the possibility of
mutating LLYlec to develop a Ley-speciﬁc binding domain. In the
work presented here a Y62H mutation was designed and con-
structed with the aim of removing the hydrogen bond between
the N-acetylglucosamine (GlcNAc) of Leb and LLYlec and instead,
gain a hydrogen bond with Ley. However, binding studies
described here show that LLYlecY62H has a greater afﬁnity for
Leb over Ley, whereas LLYlecwt has a preference for Ley over
Leb. In order to explore the molecular basis for this unexpected
ﬁnding we determined the crystal structure of LLYlecY62H in
complex with Leb and Ley. We then compared these structures
with those of the wild-type lectin domain complexed with the
same Lewis antigens. The crystallographic studies were comple-
mented by molecular dynamics simulations in order to explore
the importance of proteinmotion and interaction with the ligands
over time.
MATERIALS AND METHODS
IN SILICO DESIGN OF MUTANTS
The crystal structures of the lectin domain of LLY in complex
with Leb antigen (PDB code: 3LEK) and Ley antigen (PDB code:
3LEG) were visually inspected using Pymol1. In silico mutations
were created and assessed also using the Pymol program. Figures
were created in Pymol and using Chemaxon software2.
SURFACE PLASMON RESONANCE BIOSENSOR BINDING ANALYSIS
All surface plasmon resonance (SPR) experiments were performed
at 25◦C using a Biacore T200 instrument (GE Healthcare). Direct
1http://www.pymol.org/
2http://chemaxon.com/
assays were performed with Ley and Leb antigens (Sigma) injected
over mutant and wild-type LLYlec domain proteins immobilized
on a CM5 chip (GEHealthcare). Immobilizations were performed
in 1 × HBS-P running buffer [10 mM HEPES, 150 mM NaCl,
0.005% (w/v) Tween 20]. Binding experiments were performed in
1 × HBS-P + running buffer [10 mM HEPES, 150 mM NaCl,
0.05% (w/v) Tween 20] containing 1 mM MgCl2, 1 mM CaCl2,
and 0.2 mg/ml bovine serum albumin.
LLYlecwt and LLYlecY62H proteins were immobilized in two
separate channels on a CM5 chip using a standard amine cou-
pling protocol. Brieﬂy, the chip surface was activated with
a single 5 min injection of freshly prepared 1:1 50 mM N-
hydroxysuccinimide:200 mM 3-(N,N-dimethylamino)propyl-N-
ethylcarbodiimide. Protein coupling was achieved by three 5 min
injections of LLYlecwt or LLYlecY62H solution (50μg/ml in 10mM
sodium acetate, pH 5.0). To deactivate residual reactive sites,
lectin domain coupling was followed by a 5 min injection of 1
M ethanolamine (pH 8.5). Approximately 3000 response units
(RU; 1 RU = 1 pg of protein/mm2) of LLYlecwt (channel 2) and
4000 RU of LLYlecY62H (channel 3) were coupled. Channel 1 was
activated and blocked, as above, for use as a reference surface.
Leb and Ley were injected, in duplicate, in a twofold dilution
series from 1 mM to 7.5 μM over the immobilized wild-type and
mutant lectin domains. Thirty-second injections of Le antigen
at 40 μl/min were followed by a 60-s dissociation period. Base-
line returned to 0 almost immediately after the association phase
ended, so regeneration of the surface was not required.
Binding data were processed and analyzed using Scrubber 2
software3 (version 2.0c). Rapid association and dissociation rates
made data ﬁtting to a kinetic model and subsequent calculation
of kinetic rate constants ka and kd impractical. Consequently,
equilibrium dissociation constants (KD) were derived by ﬁtting
binding responses at equilibrium to a 1:1 steady-state afﬁnity
model available within Scrubber.
MUTAGENESIS, EXPRESSION, AND PURIFICATION OF THE LLYlec
DOMAINS
A mutant of LLYlec, LLYlecQ190C, with an N-terminal 6 × His
tag and a TEV protease cleavage site for His-tag removal, was
used in this study. The LLYlecQ190C coding region corresponds to
LLY residues 38–190 (GenBank accession number AB051299.1).
The C-terminal residue was mutated to cysteine (Q190C) for
protein labeling studies. The point mutant displays wild-type
activity and is located far from the Lewis antigen-binding site
(Farrand et al., 2008). Henceforth, LLYlecQ190C will be described
as LLYlecwt in this work. Expression was carried out in E. coli
BL21, and the protein puriﬁed using nickel resin and size exclu-
sion chromatography as previously described (Feil et al., 2012).
LLYlecwt was mutated with QuikChangeTM Site-Directed Muta-
genesis Kit (Stratagene) to create the Lewis antigen-binding site
mutant LLYlecY62H. LLYlecwt and LLYlecY62H were puriﬁed to
>95% purity, as determined by SDS gel electrophoresis. Pro-
teins were concentrated to 10 mg/ml in 10 mM Tris–HCl pH
7.2, 10 mM NaCl, and 5 mM dithiothreitol, and were stored
at −80◦C.
3www.biologic.com.au
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CRYSTALLIZATION OF THE LLYlecY62H MUTANT
All crystallizations were performed using the hanging drop vapor
diffusion method at 21◦C. 2 μl of protein was mixed with equal
volume of precipitant and hung over 0.5 ml of well solution.
LLYlecY62H crystallization conditions were determined by ﬁne
screening around the conditions that proved successful for the
wild-type protein (Feil et al., 2012): 2 M MgSO4 and 100 mM
Tris–HCl buffer pH 8.2–9.0. Optimization included the addition
of the Hampton additive screen (Hampton Research, CA, USA)
10% (v/v) in the hanging drops. The optimal crystallization condi-
tions were 2.4 M MgSO4 and 100 mM KCl with 100 mM Tris–HCl
pH 8.75–9.0. Ley and Leb antigens were soaked into LLYlecY62H
crystals by adding 1 μl 1 M MgSO4, 100 mM Tris–HCl pH 9.0,
100 mM KCl, 5 mM Ley or Leb to the crystal drop for 1 h at 21◦C.
Soaks were carried out immediately prior to cryoprotection and
ﬂash freezing in liquid nitrogen. Crystals were cryoprotected for
X-ray data collection by adding glycerol in increments of 5% (v/v)
to a ﬁnal concentration of 20% (v/v) to the crystal drops.
CRYSTALLOGRAPHIC STUDIES OF THE LLYlecY62H MUTANT
Diffraction data were collected at the MX2 beamline at the Aus-
tralian Synchrotron in Clayton, Victoria. The data collection
was controlled using Blue-Ice software (McPhillips et al., 2002).
The diffraction data were processed using the HKL2000 suite
(Otwinowski and Minor, 1997). Model building was performed
with COOT (Emsley and Cowtan, 2004) using the published
wild-type crystal structure of LLYlec (PDB code: 1LE0) as a
starting model. Data were reﬁned with REFMAC 5 (Murshu-
dov et al., 1997) from the CCP4 program suite (CCP4, 1994).
Restrained positional and isotropic temperature factor reﬁnement
was employed until convergence and the reﬁnement was mon-
itored using the Rfree residual. The Lewis antigens were fully
occupied in the binding sites of both structures and their tem-
perature factors were very similar to those of the surrounding
side-chains.
MOLECULAR MODELING OF THE LLYlec INTERACTION
WITH THE Leb AND Ley ANTIGENS
To investigate the mechanism of association and disassociation
between LLYlec and Lewis antigens four molecular models were
used: two being the published crystal structures of LLYlecwt bound
to either Leb or Ley antigen (Feil et al., 2012) and the other two
being the crystal structures of LLYlecY62H, complexed to the same
ligands, that are described here. The molecular dynamics program
NAMD (Phillips et al., 2005) was used to model ligand disasso-
ciation of each complex with a 30-ns simulation from the initial
starting bound conformation, repeated 100 times for a cumulative
simulation of 3 μs for each system. Models were initially solvated
with TIP3 water under periodic boundary conditions of dimen-
sions 48 Å × 48 Å × 64 Å. Charges were neutralized with NaCl
for a total ionic concentration of 150 mM. The bound calcium
ion seen in the crystal structures was included in the simulations.
Dynamic molecular modeling was conducted at a theoretical pH
of 7.4. Each simulation run started with an equilibration phase
of 0.5 ns, where the protein backbone and Lewis antigen was har-
monically constrained to their starting positions at 310 K and
an NPT ensemble (an isothermal and isobaric ensemble where
the number of moles (N), pressure (P), and temperature (T) are
conserved). Subsequent 30-ns production simulations were run
with no constraints at 310 K under NVT ensembles [a canonical
ensemble where the number of moles (N), volume (V), and tem-
perature (T) are conserved]. Trajectory snapshots were captured
every 100 ps. At the completion of 100 repeat simulations, all pro-
duction runs per model were consolidated into a single trajectory
and the frames root-mean-square (rms) deviation were centered,
based on the LLY alpha carbon protein backbone. The Lewis anti-
gen was then subject to clustering analysis, whereby the top 20
ligand conformational clusters with a cut-off of 1.5 Å were gen-
erated and averaged. Ligand clusters with a rms deviation value
less than 3.5 Å from the initial position were considered to be in a
bound conformation.
RESULTS
IN SILICO DESIGN OF MUTANTS
The difference between Ley and Leb antigens is the core disaccha-
ride linkage (Galβ1-4 versusGalβ1-3) with an opposing projection
of the N-acetyl glucosamine (GlcNAc) N-acetyl and –CH2OH
groups of the N-acetylglucosamine monosaccharide as shown
in Figure 1. The overall Lewis determinants maintain the same
conformation in both free and bound states.
In the crystal structure of LLYlecwt the GlcNAc of Leb is within
hydrogen bonding distance (3.3 Å) of Tyr62 (Figure 2A; Feil
et al., 2012). This interaction is not able to occur with Ley, thus
suggesting that mutating Tyr62 may alter the afﬁnity for Leb.
Various mutations of this residue were created in silico. Muta-
tion to a histidine residue would maintain structural similarity
of the binding site whilst also creating the potential for a new
interaction between the histidine side-chain and Ley as illustrated
in Figure 2B. Replacement of Tyr62 with His was expected to
remove the interaction between Leb and the hydroxyl group of
Tyr62 (Figure 2A).
SPR BIOSENSOR BINDING ANALYSIS
Puriﬁed LLYlecY62H yield was 20 mg/l E. coli BL21 culture in
Luria–Bertani (LB) broth. This yield was equivalent to that found
for LLYlecwt. The sensorgrams from SPR experiments between
the Lewis antigens (Leb and Ley) and either wt or LLYlecY62H are
shown in Figure 3. The estimated KD values are listed in Table 1.
The data indicate low afﬁnity binding interactions of the Lewis
antigens with the lectin domains. The wild-type lectin domain
(LLYlecwt) has more than threefold greater afﬁnity for Ley over
Leb. The LLYlecY62H mutant has a 1.6-fold greater preference for
Leb over Ley. The mutation causes an overall 2.5-fold decrease
in the lectin domain’s afﬁnity for Ley and doubles its afﬁnity
for Leb over the wild-type domain. Overall, the data show that
wild-type LLYlec preferentially binds Ley antigen while the mutant
LLYlecY62H exhibits higher afﬁnity for Leb than for Ley.
CRYSTAL STRUCTURES OF LLYlecY62H IN COMPLEX
WITH Ley AND Leb ANTIGENS
LLYlecY62H crystallization was optimized in 100 mM Tris pH
8.75–9.0, 2.4 M MgSO4, and 100 mM KCl. Small bipyrami-
dal crystals of dimensions 0.15 mm × 0.12 mm × 0.12 mm
appeared in 6–8 weeks. After 8 months some crystals had grown
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FIGURE 1 | Structural comparison of Leb and Ley antigens. Lewis
antigens Leb (A) and Ley (B) are structurally very similar. They differ in the
core disaccharide linkages and the opposing projections of their N -acetyl
(blue arrow) and CH2OH groups of the GlcNAc moiety.
FIGURE 2 | In silico LLYlecY62H mutant design. (A) Leb is within hydrogen bonding distance (3.3 Å) of Tyr62 from the LLYlecwt domain. (B) AY62H mutation
was designed to retain similar structural properties to tyrosine, with the possibility that it may also result in a hydrogen bond to the Ley antigen. Yellow dashed
lines denote hydrogen bonds.
to 0.25 mm × 0.2 mm × 0.2 mm. In contrast, LLYlec wt crys-
tals appeared after 5 days in 100 mM Tris pH 8.2–8.4, 2.0 M
MgSO4 with the same morphology as LLYlecY62H, but reach
the same size within 10 days (Feil et al., 2012). Lewis antigens
were soaked into crystals immediately prior to cryoprotection and
freezing.
The crystal structures of the LLYlecY62H in complex with
the Lewis antigens was performed as described in Materials and
Methods. The crystal structures have been deposited in the PDB
with codes: 4GWJ and 4GWI for the Lewis b and Lewis y com-
plexes, respectively. Data statistics for the structures are listed in
Table 2.
LLYlec adopts an eight-stranded β-sandwich fold, composed
of a ﬁve-stranded anti-parallel β-sheet on one side and a
three-stranded anti-parallel β-sheet on the other side. Three short
α-helices separate β-strands 1 and 2 and 3 and 4. There is one cal-
cium ion in the structure that is in the same position as observed
in structurally related fucolectin domains. There is also ametal ion
that is covalently bound toHis80, aswell as ﬁvewatermolecules, all
arranged in octahedral geometry. In our previous work we iden-
tiﬁed the ion as either a Ni2+ or Mg2+ ion (Feil et al., 2012) and
here we have chosen the latter possibility. The Ley and Leb antigen-
binding site is in a cleft at one end of themolecule. Amore detailed
description of the structure has been reported elsewhere (Feil et al.,
2012). In the new mutant structures some additional N-terminal
residues are observed (three extra in the Ley structure and one
extra in the Leb structure), compared to the published wild-type
structures (see Table 2).
The structures of the LLYlecwt-Ley (Figure 4A) and
LLYlecY62H-Ley (Figure 4B) superimpose very closely, with a
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FIGURE 3 | SPR measurements of immobilized LLYlecwt and LLYlecY62H.
Ley antigen and Leb antigen were injected at concentrations of 7.6–1000 μM.
(A) LLYlecwt vs Ley, (B) LLYlecY62H vs Ley, (C) LLYlecwt vs Leb, (D)
LLYlecY62H vs Leb. Responses at equilibrium ﬁtted to simple 1:1 binding
isotherms for Ley (black lines) and Leb (blue lines) interacting with (E)
LLYlecwt and (F) LLYlecY62H mutant. Duplicate binding data sets are shown.
rms deviation of the alpha carbon atoms of 0.1 Å. A third metal
ion binding site is observed in the mutant structure and we have
tentatively identiﬁed it as a Mg2+ ion binding site due to the very
high concentrations of this ion in the crystallization buffer. The
Mg2+ ion is bound between the carboxylate of Asp97 and the side-
chain carbonyl of Gln54 and four water molecules, all arranged
in octahedral geometry around the metal ion. The water structure
is the same as in LLYlecwt-Ley apart from a water molecule that
is positioned between the hydroxyl group of Tyr62 and fucose
1 (Fuc 1; Figure 4A). This water molecule is shifted by 1.4 Å
toward the NE2 of His62 in the mutant structure (Figure 4B),
compared to wild-type (Figure 4A), to optimize its interaction
with the His side-chain. LLYlecY62H forms the same 19 van der
Waals interactions with Ley compared to the wild-type protein:
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Table 1 | Estimated equilibrium dissociation constants (KD) for
LLYlecY62H and LLYlecwt domains interacting with Ley and Leb
antigens.
LLYlecwt KD (μM) LLYlecY62H KD (μM)
Ley 78 ± 9 202 ± 31
Leb 234 ± 12 127 ± 14
15 with Fuc 1, 1 with Gal, 2 with GlcNAc, and 1 with Fuc 2.
The B-factor of Ley is 53.5 Å2 in the mutant (overall B-factor of
protein is 29 Å2), compared to 38.2 Å2 in the wild-type protein
(overall B-factor of protein complex is 21 Å2). Overall, there is
no net change in the number of potential hydrogen binding and
van der Waals interactions between wild-type and mutant Ley
complexes.
Superposition of the structures of the LLYlecwt-Leb and
LLYlecY62H-Leb gives a rms deviation of the alpha carbon atoms
of 0.1 Å. In addition to the Ca2+ and Mg2+ ion binding sites
seen in the wild-type structure there is the additional Mg2+ ion
binding site as observed in the LLYlecY62H-Ley crystal structure.
In the structure of LLYlecwt-Leb there is one hydrogen bond from
the hydroxyl group of Tyr62 to the N-acetyl moiety of Leb and
a second one via a water molecule to the hydroxyl group of Fuc
1 (Figure 4C). In the LLYlecY62H-Leb structure (Figure 4D) the
bond fromTyr62 to the N-acetyl is replaced by a bifurcated hydro-
gen bond from His62 to the hydroxyl group of the GlcNAc ring
and the hydroxyl of the N-acetyl moiety off the ring. Overall,
there was a net loss of a potential hydrogen bond as the water-
mediated hydrogen bond between Tyr62 and Fuc 1 seen in the
LLYlecwt-Leb structure has been lost in LLYlecH62-Leb. The water
molecules between the protein and Leb are conserved in wild-
type and mutant structures. LLYlecY62H forms the same 23 van
der Waals interactions with Leb as does the wild-type protein:
15 with Fuc 1, 1 with Gal, 2 with GlcNAc, and 4 with Fuc 2.
The average B-factor of Leb is 43.8 Å2 in LLYlecY62H-Leb (over-
all B-factor of protein complex is 23 Å2) which is very similar to
36.7 Å2 observed in the wild-type complex (overall B-factor of
protein complex is 18 Å2). Thus, overall, there is a loss of one
potential hydrogen bond between Leb and mutant compared to
wild-type.
Superposition of the crystal structures of LLYlecY62H-Leb and
LLYlecY62H-Ley results in a rms deviation on the alpha carbons
atoms of 0.1 Å. Fuc 1 and the Gal moieties of the Ley and Leb
antigens superimpose quite well whereas GlcNAc and Fuc 2 are
shifted. GlcNAc in Leb moves 0.6 Å toward the protein due
to a water-mediated hydrogen bond between the oxygen of the
GlcNAc-CH2OH group to the backbone oxygen of His62. Like-
wise, Fuc 2 is shifted by about 0.6 Å because the same interaction
is not present in the Ley complex.
MOLECULAR SIMULATIONS OF LEWIS ANTIGEN INTERACTIONS
A total of 30,000 trajectory frames (100 × 30 ns) were collected
for each Lewis antigen in complex with either LLYlecwt or the
LLYlecY62H. In the wild-type simulations, the Ley antigen resided
within the binding pocket more than the Leb antigen (Table 3).
However, when Y62 was mutated to a His this trend was reversed,
Table 2 | Crystallographic data processing and refinement statistics
for LLYlecwt and LLYlecY62H crystal structures in complex with Ley
and Leb antigens.
LLYlecY62H-Ley LLYlecY62H-Leb
Data collection
Space group P43212 P43212
Unit cell dimensions (Å) 67.1, 67.1, 99.4 66.9, 66.9, 99.4
Wavelength (Å) 0.95 0.95
Temperature (K) 100 100
Maximum resolution (Å) 1.6 1.6
No. of observations 426,761 404,032
No. of unique reﬂections 30,563 29,510
Redundancy 14.0 13.7
Data completeness (%) 99.2 (93.7) 96.7 (79.3)
I/σI 19.6 (7.1) 16.9 (5.3)
Rmerge (%)A 11.5 (45.8) 10.9 (57.1)
Refinement
Non-hydrogen atoms
Protein 1124 1103
Water 146 150
Mg2+ 2 3
Ca2+ 1 1
Ligands 46 46
Resolution (Å) 1.6 1.6
Rwork (%)B 16.9 18.0
Rfree (%) 19.1 21.4
Rms deviations from ideal geometry
Bond lengths (Å) 0.028 0.028
Bond angles (θ) 1.4 1.4
Bonded B’s 3.9 4.1
Mean B (Å2)
Main-chain 22.8 27.0
Side-chain 28.2 31.9
Water 36.9 29.4
Ligand 53.5 43.8
Residues observed 41 to 184 43 to 184
Residues in most favored regions
of the Ramachandran plot (%)
87.7 88.4
Residues in the disallowed regions
of the Ramachandran plot (%)
0 0
The values in parentheses are for the highest resolution bin (approximately 0.1 Å
width). ARmerge = ΣhklΣi |Ii −<I>|/|<I>|, where Ii is the intensity for the ithmea-
surement of a symmetry related reﬂectionwith indices h,k,l. BRwork . = Σ||Fobs |−
|Fcalc ||/Σ|Fobs |, where Fobs and Fcalc are the observed and calculated structure
factor amplitudes, respectively.
with Leb residing in the binding pocket more than Ley. These
results are reﬂective of the SPR binding data, in that LLYlecwt has a
higher afﬁnity for Ley over Leb, whereas LLYlecY62H has a higher
afﬁnity for Leb over for Ley.
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FIGURE 4 | LLYlecwt and LLYlecY62H domains in complex with Lewis
antigens. Comparison between (A) the LLYlecwt-Ley complex (orange
carbons, greenTyr62) and (B) the LLYlecY62H-Ley complex (purple carbons,
green His62) shows that the water molecule shifts toward the histidine
residue in LLYlecY62H-Ley. The water-mediated hydrogen bond to the hydroxyl
group of Tyr62 seen in the LLYlecwt-Leb complex (cyan carbons, greenTyr62)
(C) was lost in the LLYlecwt-Leb structure (magenta carbons, greenTyr62)
(D) as this residue was replaced by His62. Hydrogen bonds are shown in gray
and water molecules as black spheres. The ﬁt of the ligands to the relevant
2Fo–F c electron density map (dark green hash), contoured at 1σ, are shown.
Lewis antigen dissociation rates were plotted as a function
of occupancy (deﬁned as <3.5 Å deviation from the original
binding site) for all 100 simulations (Figure 5). This indicated
a rapid dissociation rate which supports the SPR data where
the on and off rates were too fast to be calculated. There is
Table 3 | Cumulative totals of bound Lewis antigen over the course
of 100 independent, 30 ns simulations starting from the Lewis
bound conformation.
wt LLYlecY62H
Ley 17,260 (57.5%) 13,835 (46.1%)
Leb 14,824 (49.4%) 16,080 (53.6%)
All binding events within 3.5 Å rms deviation of the original antigen bound
conformation were considered “bound.”
an overall trend for the antigens to occupy the binding site less
as the simulations progressed. However, it is important to note
that the curves are not purely exponential and contain distinct
areas of peaks and troughs. This is indicative of the ligands mov-
ing rapidly in and out of the binding site of both LLYlecwt and
LLYlecY62H.
The simulation data reiterates the SPR ﬁnding that mutation
of LLYlecTyr62 to His62 has changed the binding speciﬁcity from
a preference for Ley by wild-type to a speciﬁcity for Leb by the
LLYlecY62H mutant.
DISCUSSION
The high level of expression of Ley on the surface of epithelial
tumor cells and low level expression elsewhere makes cell-bound
Ley a highly attractive target for anti-tumor agent delivery. In addi-
tion, the rigid nature and distinctive structure of Ley lends itself
to the ready development of highly speciﬁc protein recognition
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FIGURE 5 | Molecular dynamics modeling of the association of Lewis
antigens with the LLYlec binding sites.Traces are averaged for all 100
simulations. Overall, the Lewis antigens occupied the binding site of either
the wild-type or LLYlecY62H less as the simulation progressed. However
there are numerous areas of re-association, resulting in a spike in
occupancy.
domains, whether in antibodies or other glycan-binding
proteins.
Previously, we published the crystal structures of LLYlecwt in
complex with the Leb and Ley antigens (Feil et al., 2012). These
structures, together with computational modeling, were used
to design and construct a glycan-binding domain with altered
speciﬁcity for the Lewis antigens. The LLYlecY62H mutation was
suggested due to its structural similarity of His to Tyr and the
potential to create a new interaction with Ley.
Surface plasmon resonance binding studies showed that
LLYlecwt has a higher afﬁnity for the Ley antigen over Leb. This
relationship was reversed for the designed LLYlecY62H mutant,
i.e., the Leb antigen had higher afﬁnity than the Ley antigen. These
results were unexpected, as the molecular modeling predicted that
mutation of Tyr62 to His should decrease the number of hydro-
gen bondswith Leb and increase the number of potential hydrogen
bonds with Ley. The expectation was that themutation would lead
to an increase in afﬁnity for Ley and decrease in afﬁnity for Leb,
but in practice we found the reverse to be true.
To experimentally determine the interactions formed in the
binding site as a result of the LLYlecY62H mutation, we solved
the crystal structures of LLYlecY62H in complex with the Lewis
antigens. In the LLYlecY62H-Ley complex, there was no addi-
tional bond formation between the Lewis antigen and His62, only
a shift of a water molecule toward the His, as compared to its
position relative to Tyr62 in the wild-type (Figures 4A,B). In the
Leb complex there was a net loss of a potential hydrogen bond to
His62 (Figures 4C,D). In summary, the crystal structures did not
show the bonding as predicted from the in silico mutant model
(Figure 2) but revealed a net decrease in hydrogen bonding inter-
actions to Leb and no net change in bonding interactions with Ley.
However, the SPR data revealed that the mutant had an increased
afﬁnity for Leb and a decreased afﬁnity for Ley.
Crystal structures are a static average snapshot of what happens
in solution, so we used molecular dynamics studies to simulate the
lectin domain-Lewis antigen binding mechanism in solution. In
these simulations it was observed that the amino acid residues
around the Lewis antigen binding site are mobile, particularly
Tyr62. Thus, the inferred hydrogen bonding interactions between
protein and ligands observed in the crystal structures may not
necessarily be persistent in solution. This may help explain the
unexpected consequences of our mutation.
The molecular dynamics studies provided us with comple-
mentary results to the SPR data: both approaches showed that
the association and dissociation rates with Lewis antigens are
extremely rapid, and that the relative afﬁnities between antigens
and wild-type or LLYlecY62H domains are generally weak. The
SPR data showed the strongest interaction being that of LLYlecwt
to Ley with a KD of 78 μM and the weakest between LLYlecwt and
Leb with a KD of 234.4 μM. Relative afﬁnities of the wild-type or
LLYlecY62H binding sites for antigens was measured in the sim-
ulations by calculating how much time the Lewis antigens spent
in the binding pocket. These dynamics studies agreed with the
general trend of the biological results, suggesting that there was
a reversal of Lewis antigen afﬁnity when Tyr62 was mutated to a
His. Interestingly, and again in concurrence with SPR data, the
dynamics studies also suggest that the Lewis antigens bind weakly
and transiently to the LLYlec domain.
A recent example of protein engineering to alter Lewis antigen
speciﬁcity is that of Norovirus virion protein 1 (NoVVP1), which
speciﬁcally binds Leb (Kubota et al., 2012). However, NoVVP1 has
a deeper binding site with more extensive contacts to the Lewis
antigen structure than seen in LLYlec. A single residue (Gln) in the
Leb binding site was mutated (to Asn) with the aim of increasing
the afﬁnity of the protein for Leb. The mutation increased the
width of the binding site, allowing bonding between both fucose
rings and amino acid side-chains. As expected, the mutant protein
displayed a higher afﬁnity for Leb.
In contrast, designing a high afﬁnity Ley-speciﬁc LLYlec mutant
is more challenging: the crystal structures show that the Lewis
antigens sit in a shallow hydrophobic pocket and that the only
hydrogen bonds are between the basic residues His85, Arg112,
and Arg120, and the α1-2 linked fucose. Few contacts are made
between LLYlec residues and other carbohydrate components of
the Ley and Leb antigens (Feil et al., 2012). In addition, the struc-
tural differences between the Ley and Leb antigens are minor.
These characteristics outline the challenges involved in redesign-
ing LLYlec in order to increase its speciﬁcity for Ley. Nevertheless,
the results described herein show that, despite the strong structural
similarities between Lewis antigens Ley and Leb and the shallow
binding pocket, it is possible to alter the substrate speciﬁcity of the
LLY lectin domain.
It has previously been demonstrated that LLYlecwt domain
binds fucose alone (Farrand et al., 2008; Feil et al., 2012)
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and that the presence of LLYlec enhances the pore-forming
activity of LLY on platelets. Fucose is a commonly expressed
carbohydrate, terminally decorating cell surface glycoproteins,
including CD59 (Rudd et al., 1997; Wheeler et al., 2002), which
is also the receptor for LLY (Wickham et al., 2011). This sug-
gests the function of the lectin domain is perhaps as a “capture
mechanism,” slowing down the passing monomers and increas-
ing the local concentration of LLY in the microenvironment
of the cell surface. A localized increase in LLY concentration
would facilitate the oligomerization of LLY into prepores, prior
to pore formation and consequent cell lysis. In this scenario,
weak binding afﬁnities for the fucose moieties, as demonstrated
by SPR, would be beneﬁcial as the monomers would need
to be readily released for incorporation into assembling pre-
pore oligomers. Further studies are required to conﬁrm this
mechanism.
ACKNOWLEDGMENTS
This research was partly undertaken on the MX2 beamline at the
Australian Synchrotron, Victoria, Australia. We thank Dr. Tom
Caradoc-Davies and the other beamline staff for their assistance.
We also thankDr. JeromeWielens for assistancewithX-ray crystal-
lographic data collection. This work was partly carried out in the
Australian Cancer Research Foundation Rational Drug Discovery
Centre and funding was received from the Victorian Government
Operational Infrastructure Support Scheme to St. Vincent’s Insti-
tute. This research was supported by a Victorian Life Sciences
Computation Initiative (VLSCI) grant numberVR0021 on its Peak
Computing Facility at theUniversity of Melbourne, an initiative of
the Victorian Government, Australia. Rodney K. Tweten received
support from Grant AI037657 from the National Institutes of
Health. Susanne C. Feil was supported by a NHMRC Industry
Fellowship. Michael W. Parker is an NHMRC Research Fellow.
REFERENCES
Bergelt, S., Frost, S., and Lilie,H. (2009).
Listeriolysin O as cytotoxic compo-
nent of an immunotoxin. Protein Sci.
18, 1210–1220.
CCP4. (1994). Collaborative Compu-
tational Project. The CCP4 Suite:
programs for protein crystallography.
Acta Crystallogr. D Biol. Crystallogr.
50, 760–763.
Clarke, K., Lee, F. T., Brechbiel, M.
W., Smyth, F. E., Old, L. J., and
Scott, A. M. (2000a). In vivo biodis-
tribution of a humanized anti-Lewis
Y monoclonal antibody (hu3S193)
in MCF-7 xenografted BALB/c nude
mice. Cancer Res. 60, 4804–4811.
Clarke, K., Lee, F. T., Brechbiel, M. W.,
Smyth, F. E., Old, L. J., and Scott,
A. M. (2000b). Therapeutic efﬁcacy
of anti-Lewis(y) humanized 3S193
radioimmunotherapy in a breast can-
cer model: enhanced activity when
combined with taxol chemotherapy.
Clin. Cancer Res. 6, 3621–3628.
Emsley, P., andCowtan,K. (2004). Coot:
model-building tools for molecular
graphics. Acta Crystallogr. D Biol.
Crystallogr. 60, 2126–2132.
Farrand, S., Hotze, E., Friese, P.,
Hollingshead, S. K., Smith, D. F.,
Cummings, R. D., et al. (2008).
Characterization of a streptococcal
cholesterol-dependent cytolysin with
a lewis y and b speciﬁc lectin domain.
Biochemistry 47, 7097–7107.
Feil, S. C., Lawrence, S., Mulhern,
T. D., Holien, J. K., Hotze, E. M.,
Farrand, S., et al. (2012). Structure
of the lectin regulatory domain of
the cholesterol-dependent cytolysin
lectinolysin reveals the basis for its
lewis antigen speciﬁcity. Structure 20,
248–258.
Gowda, R. M., Ansari, A. W., and Khan,
I. A. (2003). Complete endocardial
cushion defect (complete atrioven-
tricular canal)manifested in adult life
by Streptococcus mitis endocarditis of
the common atrioventricular valve.
Int. J. Cardiol. 89, 109–110.
Hall, G. E., and Baddour, L. M. (2002).
Apparent failure of endocarditis
prophylaxis caused by penicillin-
resistant Streptococcus mitis. Am. J.
Med. Sci. 324, 51–53.
Hotze, E. M., and Tweten, R. K.
(2012). Membrane assembly of the
cholesterol-dependent cytolysin pore
complex. Biochim. Biophys. Acta
1818, 1028–1038.
Huang, I. F., Chiou, C. C., Liu, Y.
C., and Hsieh, K. S. (2002). Endo-
carditis caused by penicillin-resistant
Streptococcus mitis in a 12-year-old
boy. J. Microbiol. Immunol. Infect. 35,
129–132.
Kennedy, M. J., Jackson, M. A., and
Kearns, G. L. (2004). Delayed diag-
nosis of penicillin-resistant Strepto-
coccus mitis endocarditis following
single-dose amoxicillin prophylaxis
in a child. Clin. Pediatr. (Phila.) 43,
773–776.
Kitamura, K., Stockert, E., Garin-
Chesa, P., Welt, S., Lloyd, K. O.,
Armour, K. L., et al. (1994). Speci-
ﬁcity analysis of blood group Lewis-y
(Le(y)) antibodies generatedagainst
synthetic and natural Le(y) determi-
nants. Proc. Natl. Acad. Sci. U.S.A. 91,
12957–12961.
Kubota, T., Kumagai, A., Ito, H.,
Furukawa, S., Someya, Y., Takeda,
N., et al. (2012). Structural basis for
the recognition of Lewis antigens by
genogroup I norovirus. J Virol. 86,
11138–11150.
McPhillips, T. M., McPhillips, S. E.,
Chiu, H. J., Cohen, A. E., Dea-
con, A. M., Ellis, P. J., et al. (2002).
Blu-Ice and the Distributed Control
System: software for data acquisition
and instrument control at macro-
molecular crystallographybeamlines.
J. Synchrotron. Radiat. 9, 401–406.
Miyake, M., Taki, T., Hitomi, S., and
Hakomori, S. (1992). Correlation of
expression of H/Le(y)/Le(b) antigens
with survival in patients with carci-
noma of the lung. N. Engl. J. Med.
327, 14–18.
Murshudov, G. N., Vagin, A. A., and
Dodson, E. J. (1997). Reﬁnement
of macromolecular structures by the
maximum-likelihood method. Acta
Crystallogr. D Biol. Crystallogr. 53,
240–255.
Ohkuni, H., Todome, Y., Okibayashi, F.,
Watanabe, Y., Ohtani, N., Ishikawa,
T., et al. (1997). Puriﬁcation and
partial characterization of a novel
human platelet aggregation factor in
the extracellular products of Strep-
tococcus mitis, strain Nm-65. FEMS
Immunol. Med. Microbiol. 17, 121–
129.
Otwinowski, Z., and Minor, W. (1997).
Processing of X-ray diffraction data
collected in the oscillation mode.
Methods Enzymol. 276, 307–326.
Phillips, J. C., Braun, R., Wang, W.,
Gumbart, J., Tajkhorshid, E., Villa,
E., et al. (2005). Scalable molecular
dynamics with NAMD. J. Comput.
Chem. 26, 1781–1802.
Polekhina, G., Giddings, K. S.,
Tweten, R. K., and Parker, M.
W. (2005). Insights into the action
of the superfamily of cholesterol-
dependent cytolysins from studies of
intermedilysin. Proc. Natl. Acad. Sci.
U.S.A. 102, 600–605.
Rossjohn, J., Feil, S. C., McKinstry, W.
J., Tweten, R. K., and Parker, M. W.
(1997). Structure of a cholesterol-
binding, thiol-activated cytolysin and
a model of its membrane form. Cell
89, 685–692.
Rudd, P. M., Morgan, B. P., Wormald,
M. R., Harvey, D. J., Van Den Berg,
C. W., Davis, S. J., et al. (1997). The
glycosylation of the complement reg-
ulatory protein, human erythrocyte
CD59. J. Biol. Chem. 272, 7229–
7244.
Sakamoto, J., Furukawa, K., Cordon-
Cardo, C., Yin, B. W., Rettig, W.
J., Oettgen, H. F., et al. (1986).
Expression of Lewisa, Lewisb, X, and
Y blood group antigens in human
colonic tumors andnormal tissue and
in human tumor-derived cell lines.
Cancer Res. 46, 1553–1561.
Scott, A. M., Geleick, D., Rubira,
M., Clarke, K., Nice, E. C.,
Smyth, F. E., et al. (2000). Con-
struction, production, and charac-
terization of humanized anti-Lewis
Y monoclonal antibody 3S193 for
targeted immunotherapy of solid
tumors. Cancer Res. 60, 3254–3261.
Westwood, J. A., Murray, W. K., Triv-
ett, M., Haynes, N. M., Solomon,
B., Mileshkin, L., et al. (2009).
The Lewis-Y carbohydrate antigen is
expressed by many human tumors
and can serve as a target for genet-
ically redirected T cells despite the
presence of soluble antigen in serum.
J. Immunother. 32, 292–301.
Westwood, J. A., Smyth, M. J., Teng, M.
W., Moeller, M., Trapani, J. A., Scott,
A. M., et al. (2005). Adoptive transfer
of T cells modiﬁed with a human-
ized chimeric receptor gene inhibits
growth of Lewis-Y-expressing tumors
in mice. Proc. Natl. Acad. Sci. U.S.A.
102, 19051–19056.
Wheeler, S. F., Rudd, P. M., Davis,
S. J., Dwek, R. A., and Har-
vey, D. J. (2002). Comparison of
the N-linked glycans from soluble
and GPI-anchored CD59 expressed
in CHO cells. Glycobiology 12,
261–271.
Wickham, S. E., Hotze, E. M., Farrand,
A. J., Polekhina, G., Nero, T. L., Tom-
linson, S., et al. (2011). Mapping the
intermedilysin-human CD59 recep-
tor interface reveals a deep corre-
spondence with the binding site on
www.frontiersin.org November 2012 | Volume 3 | Article 330 | 9
“ﬁmmu-03-00330” — 2012/11/5 — 17:59 — page 10 — #10
Lawrence et al. Lectinolysin Lewis antigen speciﬁcity
CD59 for complement binding pro-
teins C8α and C9. J. Biol. Chem. 286,
20952–20962.
Yin, B. W., Finstad, C. L., Kitamura,
K., Federici, M. G., Welshinger, M.,
Kudryashov, V., et al. (1996). Sero-
logical and immunochemical anal-
ysis of Lewis y (Ley) blood group
antigen expression in epithelial ovar-
ian cancer. Int. J. Cancer 65,
406–412.
Yuriev, E., Farrugia, W., Scott, A.
M., and Ramsland, P. A. (2005).
Three-dimensional structures of
carbohydrate determinants of Lewis
system antigens: implications for
effective antibody targeting of
cancer. Immunol. Cell Biol. 83,
709–717.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 05 September 2012; paper
pending published: 15 September 2012;
accepted: 17 October 2012; published
online: 05 November 2012.
Citation: Lawrence SL, Feil SC, Holien
JK, Kuiper MJ, Doughty L, Dolezal O,
Mulhern TD, Tweten RK and Parker
MW (2012) Manipulating the Lewis
antigen speciﬁcity of the cholesterol-
dependent cytolysin lectinolysin. Front.
Immun. 3:330. doi: 10.3389/ﬁmmu.
2012.00330
This article was submitted to Frontiers in
Molecular Innate Immunity, a specialty
of Frontiers in Immunology.
Copyright © 2012 Lawrence, Feil, Holien,
Kuiper, Doughty, Dolezal, Mulhern,
Tweten and Parker. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Immunology | Molecular Innate Immunity November 2012 | Volume 3 | Article 330 | 10
